| Anticoagulant therapy and incidence of bleeding | ||||
| Patel, M. R. et al. (2011) | RCT (n = 14,264) | Rivaroxaban (Xarelto) 20mg or 15 mg daily for patients with a creatinine clearance of 30 to 49 mL per minute vs. dose adjusted (target international normalized ratio [INR], 2.0 to 3.0) Warfarin | 71.2 + 9.42 | Risk of major bleeding 1475 patients in the rivaroxaban group and 1449 patients in the warfarin group, respectively; hazard ratio in the rivaroxaban group, 1.03; 95% CI, 0.96 to 1.11; P = 0.442). Rates of major bleeding were similar in the rivaroxaban and warfarin groups (3.6% and 3.4%, respectively; P = 0.58) [18] . |
| Rutherford O.C W. et al. (2020) | Randomized cohort trial (n = 20,504) | Dabigatranvsrivaroxaban | Dabigatran 70.9 + 10.95 Rivaroxaban 70.9 + 11.21 | A major bleeding event occurred at a rate of 1.40/100 person-years in the dabigatran group, and 1.93 in the rivaroxaban group (HR 0.75; 95% CI 0.64 - 0.88). |
| Randomized cohort trial (n = 27,298) | Rivaroxaban vs. apixaban | Rivaroxaban 72.7 + 11.08 Apixaban 72.7 + 11.66 | The event rates of major bleeding were 1.76/100 person-years vs. 2.10/100 person-years in the apixaban- and rivaroxaban groups, respectively (HR 0.79; 95% CI 0.68 - 0.91) [13] . | |